» Articles » PMID: 27548357

Significance of Cystatin C for Early Diagnosis of Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography

Overview
Journal Med Sci Monit
Date 2016 Aug 23
PMID 27548357
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

BACKGROUND Contrast-induced nephropathy is acute kidney injury caused by contrast medium exposure. Serum creatinine is the clinical diagnostic standard, but it does not yield quick results. The serum level of cystatin C is stable and it can reflect renal function sensitively. The study aimed to assess the usefulness of cystatin C for early diagnosis of contrast-induced nephropathy in patients undergoing coronary angiography. MATERIAL AND METHODS We included 300 patients who underwent CAG. According to the sCr at 48 h, patients were divided into 2 groups: CIN group and non-CIN group. Their demographics and basal renal function were recorded. Changes in sCr, Cys C, and e GFR were compared at the same time. ROC analysis was used to assess the sensitivity and specificity of Cys C in the early diagnosis of CIN. RESULTS Comparison of basal renal function and serum level of Cys C showed no significant differences between the 2 groups. Serum level of Cys C increased significantly at 24 h (p<0.001), and sCr increased significantly at 48 h. ROC analysis showed that the AUC of the change in Cys C between baseline and 24 h was 0.936 (95% CI: 0.879-0.992, p=0.000) and the optimum cut-off level was 0.26 mg/L (sensitivity=89.7% and specificity=95.6%). CONCLUSIONS The concentration change of Cys C is better than sCr as a biomarker in the early detection of CIN.

Citing Articles

NGAL as Biomarker of Clinical and Subclinical Damage of Kidney Function after Coronary Angiography.

Petrova I, Alexandrov A, Vladimirov G, Mateev H, Bogov I, Paskaleva I Diagnostics (Basel). 2023; 13(6).

PMID: 36980488 PMC: 10047760. DOI: 10.3390/diagnostics13061180.


Renoprotective Effect of Vardenafil and Avanafil in Contrast-Induced Nephropathy: Emerging Evidence from an Animal Model.

Zisis I, Georgiadis G, Docea A, Calina D, Cercelaru L, Tsiaoussis J J Pers Med. 2022; 12(5).

PMID: 35629096 PMC: 9144719. DOI: 10.3390/jpm12050670.


Effect of Calcium Dobesilate in Preventing Contrast-Induced Nephropathy in Patients with Diabetes and Chronic Kidney Disease.

Zhang H, Guo S, Xue Z, Zhang Y, Wang J, Che J Clinics (Sao Paulo). 2021; 76:e2942.

PMID: 34669873 PMC: 8491593. DOI: 10.6061/clinics/2021/e2942.


Elevation of preoperative cystatin C as an early predictor of contrast-induced nephropathy in patients receiving percutaneous coronary intervention.

Gu G, Yu N, Zhou Y, Cui W Singapore Med J. 2021; 63(8):450-455.

PMID: 33472331 PMC: 9584075. DOI: 10.11622/smedj.2021002.


Predictive value of cystatin C and neutrophil gelatinase-associated lipocalin in contrast-induced nephropathy: A meta-analysis.

He Y, Deng Y, Zhuang K, Li S, Xi J, Chen J PLoS One. 2020; 15(4):e0230934.

PMID: 32240220 PMC: 7117687. DOI: 10.1371/journal.pone.0230934.


References
1.
Fehr T, Rickli H . Reply to Sjöström et al. Cystatin C and creatinine for assessment of kidney function: differences in pharmacokinetics--and more!. Clin Nephrol. 2004; 62(4):327-8. DOI: 10.5414/cnp62327. View

2.
McCullough P . Outcomes of contrast-induced nephropathy: experience in patients undergoing cardiovascular intervention. Catheter Cardiovasc Interv. 2006; 67(3):335-43. DOI: 10.1002/ccd.20658. View

3.
. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1):S1-266. View

4.
Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko J, Poniatowski B, Pawlak K . NGAL (neutrophil gelatinase-associated lipocalin) and cystatin C: are they good predictors of contrast nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine?. Int J Cardiol. 2007; 127(2):290-1. DOI: 10.1016/j.ijcard.2007.04.048. View

5.
HIRSCHBERG R, Kopple J, Lipsett P, Benjamin E, Minei J, Albertson T . Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int. 1999; 55(6):2423-32. DOI: 10.1046/j.1523-1755.1999.00463.x. View